Xi'an Chupu Biotechnology

Xi'an Chupu Biotechnology is a Chinese biopharmaceutical company focused on the development of innovative metabolic and endocrine therapies. The company specializes in the design and optimization of peptide-based drugs and small molecule agonists, particularly targeting the GLP-1 and GIP pathways for the treatment of obesity and type 2 diabetes. Chupu Bio leverages a proprietary oral delivery technology to overcome the bioavailability challenges typically associated with peptide therapeutics. Their current pipeline is primarily in the discovery and pre-clinical stages, aiming to provide more convenient and effective treatment options for chronic metabolic diseases.